Beijing, Aug 24, 2026 — China’s Center for Medical Device Evaluation (CMDE) unveiled the 17th priority review roster of 2026, clearing three devices for expedited market approval, including diagnostic kits for rare diseases and a clinically urgent oncology biomarker assay.
Priority Review Roster
| No. | Application No. | Product | Applicant | Priority Rationale |
|---|---|---|---|---|
| 1 | CSZ2600245 | Unconjugated Bilirubin Assay Kit (LC-MS/MS) | Shenzhen Huiyun Biotechnology Co., Ltd. | Rare disease diagnosis/treatment with significant clinical advantage |
| 2 | CSZ2600259 | Claudin18.2 (EPR19202) Antibody Reagent (IHC) | Guangzhou Ampere Medical Technology Co., Ltd. | Clinically urgent; no equivalent approved in China |
| 3 | CSZ2600262 | Leber Hereditary Optic Neuropathy Gene Detection Kit (PCR-Fluorescence Probe) | Wenzhou Puxi Gene Technology Co., Ltd. | Rare disease diagnosis with clinical advantage; clinically urgent with no domestic equivalent |
Regulatory Framework
The designations fall under the Medical Device Priority Review Procedure, which grants accelerated assessment pathways for products meeting criteria such as rare disease relevance, clinical urgency, or absence of approved domestic alternatives. The public comment window runs from Aug 24 to Aug 31, 2026. Stakeholders may file objections via email to gcdivision@cmde.org.cn.
Market Impact Analysis
The roster underscores Beijing’s continued regulatory favor toward rare disease diagnostics and precision oncology tools. Shenzhen Huiyun and Wenzhou Puxi both secured slots via the rare disease pathway—a segment that has drawn intensified policy support as China expands its rare disease catalog and reimbursement frameworks.
Guangzhou Ampere’s Claudin18.2 immunohistochemistry reagent addresses a high-priority oncology target, notably in gastric cancer, where the biomarker has gained global traction as a therapeutic and diagnostic anchor. Securing priority status positions the firm to capture first-mover advantage in a market currently lacking approved domestic equivalents.
For investors, the list offers a near-term indicator of which clinical domains—rare metabolic disorders, hereditary optic neuropathy, and GI oncology—regulators are actively fast-tracking. The concentrated representation of molecular diagnostics (LC-MS/MS, PCR-fluorescence, IHC) also signals CMDE’s comfort with advanced testing platforms in the priority queue.
Forward-Looking Statement
Industry observers expect the rare disease and clinically urgent pathways to dominate upcoming priority review cycles through year-end, as Beijing aligns device regulation with broader pharmaceutical and diagnostic policy goals. Companies with pipelines in hereditary disease genotyping, oncology companion diagnostics, and mass-spectrometry-based assays are likely to benefit from shortened approval timelines, provided they can demonstrate clear clinical superiority or address unmet domestic need. The Aug 31 comment deadline is expected to pass without material objections, allowing the three applicants to advance toward final registration decisions by late 2026 or early 2027.-China Health Reform Pulse
Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260824160407126.html